Intrinsic Value of S&P & Nasdaq Contact Us

Biofrontera Inc. BFRIW NASDAQ

NASDAQ Capital Marke • Healthcare • Drug Manufacturers - Specialty & Generic • US • USD

SharesGrow Score
32/100
0/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Biofrontera Inc. (BFRIW) — This stock currently has no analyst coverage. No price targets, ratings, or earnings estimates are available. This is common for preferred shares, warrants, OTC-traded securities, and smaller companies that are not followed by Wall Street analysts.

Analysts estimate Earnings Per Share (EPS) of $-3.04 and revenue of $0.04B for the next fiscal year.

Earnings Per Share (EPS) track record: 2024: actual $0.00 vs est $-3.04 (beat +99.9%). 2025: actual $-1.04 vs est $-1.39 (beat +25.2%). Analyst accuracy: 0%.

EPS Estimates — BFRIW

0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024 Actual –$0.00 vs Est –$3.04 ▲ 94,743.8% off
2025 Actual –$1.04 vs Est –$1.39 ▲ 33.7% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.

Revenue Estimates — BFRIW

96%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024 Actual $0.037B vs Est $0.039B ▼ 5.4% off
2025 Actual $0.042B vs Est $0.041B ▲ 2.3% off
Revenue Trend
Moderate revenue growth trend. Analysts expect stable revenue going forward.
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message